ArticleEnvironmental research2025
Gestational PFAS concentrations in association with maternal depression and perceived stress during pregnancy and postpartum in the ECHO cohort.
Article in Environmental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Depression and perceived stress are common perinatal morbidities. We assessed associations between prenatal per- and polyfluoroalkyl substances (PFAS) with prenatal and postpartum depression and perceived stress. We analyzed concentrations of 7 PFAS in maternal plasma or serum in the Environmental influences on Child Health Outcomes (ECHO) cohort (n = 4403). We ascertained prenatal depression diagnosis; prenatal and postpartum depressive symptom severity using a Patient-Reported Outcomes Measurement Information System Depression (PROMIS-D) t-score; and prenatal and postpartum perceived stress using a Perceived Stress Scale (PSS) t-score. Linear and modified Poisson models assessed associations of PFAS with outcomes. Quantile g-computation assessed PFAS mixtures. We evaluated effect modification by nativity and Social Vulnerability Index. N-MeFOSAA was positively associated, PFDA was inversely associated, and PFOS and PFOA were nonlinearly associated with multiple outcomes. For example, the highest category of N-MeFOSAA was associated with 0.93 (95 %CI: -0.17, 2.03) units higher postpartum PROMIS-D t-scores, and 1.88 (95 %CI: 1.05, 2.72) units higher postpartum PSS t-scores. In contrast, the highest category of PFDA was associated with 25 % (risk ratio [RR]: 0.75 [95 %CI: 0.56, 1.01]) lower risk of depression diagnosis and 0.83 (95 %CI: 0.14, 1.51) units lower prenatal PSS t-scores. The middle and highest categories of PFOS were associated with 26 % (RR: 1.26 [95 %CI: 1.05,1.52]) higher and 38 % (RR: 0.62 [95 %CI: 0.37, 1.05]) lower risk of depression diagnosis; and 0.97 (95 %CI: 0.09, 1.84) units higher and 0.04 (95 %CI: -1.53, 1.62) units lower prenatal PSS t-score. Some PFAS may be associated with altered depressive symptoms and perceived stress; investigation into mechanisms is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.